Methods of enhancing mucosal hydration and mucosal clearance...

Details Methods of enhancing mucosal hydration and mucosal clearance... Methods of enhancing mucosal hydration and mucosal clearance...

2011-07-19

2011-07-19

Henley, III, Raymond J (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S255050

Reexamination Certificate

active

07981898

ABSTRACT:
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

REFERENCES:
patent: 4501729 (1985-02-01), Boucher et al.
patent: 5656256 (1997-08-01), Boucher et al.
patent: 5725842 (1998-03-01), Boucher, Jr. et al.
patent: 5817028 (1998-10-01), Anderson
patent: 5876700 (1999-03-01), Boucher, Jr. et al.
patent: 6264975 (2001-07-01), Boucher, Jr.
patent: 6475509 (2002-11-01), Boucher, Jr.
patent: 6607741 (2003-08-01), Boucher, Jr.
patent: 6613345 (2003-09-01), Boucher, Jr.
patent: 6753164 (2004-06-01), Ni et al.
patent: 6858614 (2005-02-01), Johnson
patent: 6858615 (2005-02-01), Johnson
patent: 6903105 (2005-06-01), Johnson
patent: 6926911 (2005-08-01), Boucher, Jr.
patent: 6995160 (2006-02-01), Johnson
patent: 7026325 (2006-04-01), Johnson
patent: 7030117 (2006-04-01), Johnson
patent: 7056524 (2006-06-01), Boucher, Jr.
patent: 7064129 (2006-06-01), Johnson et al.
patent: 7186833 (2007-03-01), Johnson
patent: 7189719 (2007-03-01), Johnson
patent: 7192958 (2007-03-01), Johnson
patent: 7192959 (2007-03-01), Johnson
patent: 7192960 (2007-03-01), Johnson
patent: 7241766 (2007-07-01), Johnson
patent: 7247636 (2007-07-01), Johnson
patent: 7247637 (2007-07-01), Johnson et al.
patent: 2004/0198747 (2004-10-01), Johnson
patent: 2004/0198749 (2004-10-01), Johnson
patent: 2005/0059676 (2005-03-01), Johnson
patent: 2005/0080092 (2005-04-01), Johnson
patent: 2005/0080093 (2005-04-01), Johnson et al.
patent: 2005/0090505 (2005-04-01), Johnson et al.
patent: 2005/0228182 (2005-10-01), Johnson et al.
patent: 2006/0040954 (2006-02-01), Johnson
patent: 2006/0052394 (2006-03-01), Johnson et al.
patent: 2006/0052395 (2006-03-01), Johnson et al.
patent: 2006/0063780 (2006-03-01), Johnson
patent: 2006/0142306 (2006-06-01), Johnson
patent: 2006/0142581 (2006-06-01), Johnson
patent: 2006/0205738 (2006-09-01), Johnson et al.
patent: 2007/0032509 (2007-02-01), Johnson et al.
patent: WO-03/070182 (2003-08-01), None
patent: WO-03070184 (2003-08-01), None
patent: WO-2005/044180 (2005-05-01), None
U.S. Appl. No. 12/249,175, filed Oct. 10, 2008, Boucher, et al.
U.S. Appl. No. 12/304,006, filed Dec. 9, 2008, Johnson, et al.
U.S. Appl. No. 12/304,042, filed Dec. 9, 2008, Johnson.
U.S. Appl. No. 12/304,040, filed Dec. 9, 2008, Johnson.
U.S. Appl. No. 10/920,527, filed Aug. 18, 2004, Hopkins.
U.S. Appl. No. 11/573,693, filed Feb. 14, 2007, Johnson.
U.S. Appl. No. 11/573,413, filed Feb. 8, 2007, Johnson.
U.S. Appl. No. 11/573,421, filed Feb. 8, 2007, Johnson.
U.S. Appl. No. 11/695,936, filed Apr. 3, 2007, Johnson.
U.S. Appl. No. 11/696,003, filed Apr. 3, 2007, Johnson.
U.S. Appl. No. 11/851,803, filed Sep. 7, 2007, Johnson, et al.
U.S. Appl. No. 60/495,725, filed Aug. 18, 2003, Johnson.
U.S. Appl. No. 60/495,720, filed Aug. 18, 2003, Johnson.
U.S. Appl. No. 60/495,712, filed Aug. 18, 2003, Johnson.
U.S. Appl. No. 60/602,313, filed Aug. 18, 2004, Johnson.
U.S. Appl. No. 60/602,327, filed Aug. 18, 2004, Johnson.
U.S. Appl. No. 60/812,091, filed Jun. 9, 2006, Johnson.
U.S. Appl. No. 60/812,077, filed Jun. 9, 2006, Johnson, et al.
U.S. Appl. No. 60/812,078, filed Jun. 9, 2006, Johnson.
U.S. Appl. No. 60/842,669, filed Sep. 7, 2006, Johnson, et al.
U.S. Appl. No. 60/842,963, filed Sep. 8, 2006, Johnson, et al.
U.S. Appl. No. 60/845,171, filed Sep. 18, 2006, Johnson, et al.
U.S. Appl. No. 60/909,818, filed Apr. 3, 2007, Johnson, et al.
U.S. Appl. No. 60/978,887, filed Oct. 10, 2007, Boucher, et al.
U.S. Appl. No. 60/978,874, filed Oct. 10, 2007, Boucher, et al.
U.S. Appl. No. 60/987,663, filed Nov. 13, 2007, Johnson, et al.
U.S. Appl. No. 61/013,387, filed Dec. 13, 2007, Johnson, et al.
U.S. Appl. No. 61/030,313, filed Feb. 21, 2008, Johnson.
U.S. Appl. No. 61/031,466, filed Feb. 26, 2008, Johnson.
U.S. Appl. No. 12/171,814, filed Jul. 11, 2008, Johnson. et al.
U.S. Appl. No. 12/171,867, filed Jul. 11, 2008, Johnson. et al.
U.S. Appl. No. 12/171,897, filed Jul. 11, 2008, Johnson. et al.
U.S. Appl. No. 12/190,022, filed Aug. 12, 2008, Johnson.
U.S. Appl. No. 61/079,989, filed Jul. 11, 2008, Boucher, et al.
U.S. Appl. No. 12/179,353, filed Jul. 24, 2008, Johnson.
U.S. Appl. No. 11/960,989, filed Dec. 20, 2007, Johnson, et al.
U.S. Appl. No. 11/950,674, filed Dec. 5, 2007, Johnson, et al.
U.S. Appl. No. 11/835,902, filed Aug. 8, 207, Johnson, et al.
U.S. Appl. No. 12/049,946, filed Mar. 17, 2008, Johnson, et al.
U.S. Appl. No. 12/049,968, filed Mar. 17, 2008, Johnson, et al.
U.S. Appl. No. 12/049,894, filed Mar. 17, 2008, Johnson, et al.
U.S. Appl. No. 12/050,010, filed Mar. 17, 2008, Johnson.
U.S. Appl. No. 12/049,993, filed Mar. 17, 2008, Johnson.
U.S. Appl. No. 12/050,019, filed Mar. 17, 2008, Johnson.
U.S. Appl. No. 12/061,837, filed Apr. 3, 2008, Johnson, et al.
U.S. Appl. No. 12/061,864, filed Apr. 3, 2008, Johnson, et al.
U.S. Appl. No. 12/098,581, filed Apr. 7, 2008, Johnson.
Bennett, W.D. et al. (1996) “Effect of Uridine 5′-Triphosphate Plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis”,Am J Respir Crit Care Med.vol. 153, pp. 1796-1801.
Boucher, R.C. (2007), “Airway Surface Dehydration In Cystic Fibrosis: Pathogenesis and Therapy”,Annu. Rev. Med.vol. 58, pp. 157-170.
Boucher, R.C. (2007) “Evidence for airway surface dehydration as the inillating event in CF airway disease”,Journal of Internal Medicine, vol. 261, pp. 5-16.
Boucher, R.C., (2007), “Cystic fibrosis: a disease of vulnerability to airway surface dehydration”,Trends in Molecular Medicine, vol. 13(6), pp. 231-240.
Cline, D. et al. (2002), “Predicting the Quality of Powders for Inhalation from Surface Energy and Area”,Pharmaceutical Research, vol. 19(9), pp. 1274-1277.
Clunes, M. et al. (2008), “Front-runners for pharmacotherapeutic correction of the airway ion transport defect in cystic fibrosis”,Current Opinion in Pharmacology, vol. 8, pp. 292-299.
Donaldson, S.H. et al. (2006), “Mucus Clearance and Lung Fuction in Cystic Fibrosis with Hypertonic Saline”,The New England Journal of Medicine, vol. 354, pp. 241-250.
Elkins. M.R. et al. (2006), “A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis”,The New England Journal of Medicine, vol. 354(3), pp. 229-240.
Gowen, C.W. et al. (1986) “Increased nasal potential difference and amiloride sensitivity in neonates with cystic fibrosis”,The Journal of Pediatrics, vol. 108(4), pp. 517-521.
Hirsh, A. J. et al. (2006) “Design, Synthesis, and Structure-Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers: Drugs for Cystic Fibrosis and Chronic Bronchitis”,Journal of Medicinal Chemistry, vol. 49, pp. 4098-4115.
Hirsh, A.J. et al. (2009) “Pharmacological Properties ofN-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonte (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease”,The Journal of Pharmacology and Experimental Therapeutics, vol. 325(1), pp. 77-88.
Hirsh, A.J. et al. ((2004), “Evaluation of Second Generation Amiloride Analogs as Therapy for Cystic Fibrosis Lung Disease”,The Journal of Pharmacology and Experimental Therapeutics, vol. 311(3), pp. 929-938.
Hofmann, T. et al. (1998), “Effects of Topically Delivered Benzamil and Amiloride on Nasal Potential Difference in Cystic Fibrosis”,Am. J. Resp. Crit. Care Med, vol. 157, pp. 1844-1849.
Jones, K.M. et al. (1997), “Pharmacokinetics of Amiloride after Inhalation and Oral Administration in Adolescents and Adults with Cystic Fibrosis”,Pharmacotherapy, vol. 17(2) pp. 263-270.
Knowles, M.R. et al. (1991) “Aerosolized Amiloride as Treatment of Cystic Fibrosis Lung D

Affiliated with

Also associated with

Rating

Methods of enhancing mucosal hydration and mucosal clearance... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of enhancing mucosal hydration and mucosal clearance..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of enhancing mucosal hydration and mucosal clearance... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2670741